Advanced search
Publication Cover
Postgraduate Medicine Volume 124, 2012 - Issue 4
Submit an article Journal homepage
151
Views
12
CrossRef citations to date
0
Altmetric
Clinical Focus: Diabetes and Concomitant Disorders

Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin

Serge A. Jabbour Professor of Medicine and Director, Division of Endocrinology, Diabetes and Metabolic Diseases, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PACorrespondence[email protected]
, MD, FACP, FACE,
Jean M. Whaley Bristol-Myers Squibb, Metabolic Diseases Discovery Biology, Research and Development, Princeton, NJ
, ScD,
Mark Tirmenstein Bristol-Myers Squibb, Drug Safety Evaluation, Research and Development, New Brunswick and Princeton, NJ
, PhD,
Simon M. Poucher AstraZeneca Pharmaceuticals, CVGI Discovery, Macclesfield, Cheshire, UK
, PhD,
Timothy P. Reilly Bristol-Myers Squibb, Drug Safety Evaluation, Research and Development, New Brunswick and Princeton, NJ
, PhD, DABT,
David W. Boulton Bristol-Myers Squibb, Discovery Medicine and Clinical Pharmacology, Princeton, NJ
, PhD,
JoAnne Saye AstraZeneca Pharmaceuticals, Global Safety Assessment, Research and Development, Wilmington, DE
, PhD,
James F. List Bristol-Myers Squibb, Global Clinical Research, Research and Development, Princeton, NJ
, MD, PhD &
Shamik Parikh AstraZeneca Pharmaceuticals, Cardiovascular, Clinical Development, Wilmington, DE
, MD show all
Pages 62-73 | Published online: 13 Mar 2015

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Stanley S. Schwartz & Intekhab Ahmed. (2016) Sodium–glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes. Current Medical Research and Opinion 32:5, pages 907-919.
Read now
Serge A. Jabbour. (2014) SGLT2 Inhibitors to Control Glycemia in Type 2 Diabetes Mellitus: A New Approach to an Old Problem. Postgraduate Medicine 126:1, pages 111-117.
Read now

Articles from other publishers (10)

Julio Rosenstock, Shira Perl, Eva Johnsson, Ricardo García‐Sánchez & Stephan Jacob. (2019) Triple therapy with low‐dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism 21:9, pages 2152-2162.
Crossref
Jian Li, Yanping Gong, Chunlin Li, Yanhui Lu, Yu Liu & Yinghong Shao. (2017) Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus. Medicine 96:27, pages e7201.
Crossref
William T. Cefalu, Lawrence A. Leiter, Tjerk W.A. de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg & Shamik J. Parikh. (2015) Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. Diabetes Care 38:7, pages 1218-1227.
Crossref
Julio Rosenstock, Lars Hansen, Pamela Zee, Yan Li, William Cook, Boaz Hirshberg & Nayyar Iqbal. (2015) Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin. Diabetes Care 38:3, pages 376-383.
Crossref
S. Parikh, J. Wilding, S. Jabbour & E. Hardy. (2015) Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice 69:2, pages 186-198.
Crossref
Qian Zhang, Jingtao Dou & Juming Lu. (2014) Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses. Diabetes Research and Clinical Practice 105:3, pages 313-321.
Crossref
Oliver Schnell, Hasan Alawi, Tadej Battelino, Antonio Ceriello, Peter Diem, Anne-Marie Felton, Kari Harno, Ilhan Satman & Bruno Vergès. (2014) The Role of Self-Monitoring of Blood Glucose in Patients Treated With SGLT-2 Inhibitors. Journal of Diabetes Science and Technology 8:4, pages 783-790.
Crossref
Timothy P. Reilly, Michael J. Graziano, Evan B. Janovitz, Thomas E. Dorr, Craig Fairchild, Francis Lee, Jian Chen, Tai Wong, Jean M. Whaley & Mark Tirmenstein. (2014) Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus. Diabetes Therapy 5:1, pages 73-96.
Crossref
Theodoros P. Angelopoulos & John Doupis. (2014) Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors—Fighting Diabetes from a New Perspective. Advances in Therapy 31:6, pages 579-591.
Crossref
Pitchai Balakumar, Karupiah Sundram & Sokkalingam A. Dhanaraj. (2014) Dapagliflozin: Glucuretic action and beyond. Pharmacological Research 82, pages 34-39.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.